Clinical trial
Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease
NCT02055079 · Medical University of Vienna, Other · Unknown status
Key facts
| NCT number | NCT02055079 |
|---|---|
| Title | Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease |
| Official title | Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease - The Vienna RAP Study |
| Acronym | RAP |
| Lead sponsor | Medical University of Vienna, Other |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Polycystic Kidney, Type 1 Autosomal Dominant Disease, Type 2 Autosomal Dominant Disease |
| Intervention type | Drug |
| Interventions | Sirolimus, Placebo |
| Enrollment | 68 |
| Start date | Apr 1, 2014 |
| Primary completion | Apr 1, 2019 |
| Completion | Dec 1, 2019 |
| First posted | Feb 4, 2014 |
| Last update posted | Oct 31, 2018 |
| Countries | Austria |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: